Tafenoquine

Caitlin Soto , PharmD, BCIDP, Edina Avdic, Pharm.D.
Pediatric Dosing Author: Bethany Sharpless Chalk, Pharm.D., BCPPS

INDICATIONS

FDA

  • Two different brand names were FDA-approved in 2018:
    • Krintafel™ — radical cure (prevention of relapse) of Plasmodium vivax malaria in patients ≥16 years old who are receiving chloroquine therapy for acute P. vivax infection.
      • Please note that tafenoquine is NOT indicated for the treatment of acute P. vivax malaria.
      • Concomitant use with antimalarials other than chloroquine is not recommended because of the risk of P. vivax recurrence.
    • Arakoda™ — prophylaxis of malaria in patients ≥18 years of age.

NON-FDA APPROVED USES

  • P. ovale radical cure:
    • Off-label radical cure in patients ≥16 years with normal quantitative G6PD activity when chloroquine/hydroxychloroquine is used for acute therapy.
  • Babesia microti babesiosis:
    • Investigational salvage therapy for persistent or relapsing infection, particularly in highly immunocompromised patients with failure or resistance to standard regimens.
    • Clinical experience is limited to case reports/small case series.
      • Tafenoquine is not FDA-approved for babesiosis, and no standardized dose or duration has been established.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: November 7, 2026